spacer
home > ebr > summer 2003 > the cognitive assessment of herbal products - are the effects imagined or real?
PUBLICATIONS
European Biopharmaceutical Review

The Cognitive Assessment of Herbal Products - Are the Effects Imagined or Real?

With the recent proposal by the EU Commission for a Directive on so-called 'traditional herbal products', it would seem that it is no longer possible for companies producing herbal products to simply put them in the marketplace. For years now, many herbal products have been marketed as cognitive enhancers or herbal antidepressants with little or no evidence to substantiate the claims except that they 'have been used traditionally for centuries'. The new EU Directive insists that any herbal products be treated as the medicines they claim to be, rather than seeking the protection of national food laws. Therefore, new and existing herbal compounds will be required to prove 'qualitative, efficacious and safe' results in structured clinical trials. The main disadvantage of the new law, which will have a major adverse impact on the trade of herbal remedies, is that products which cannot claim 30 years of established use will have to seek market authorisation as medicinal products. In this sense, the new Directive's ostensible intention to minimise cost burdens on small and medium-sized producers will also have the unpleasant effect of deleting several little-known herbal products from the EU market altogether.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tamsin Manktelow, Scientific Development Manager, and Andrea Zangara, Research Associate, at Cognitive Drug Research Ltd

Having graduated from the University of Reading with a BA Hons in Psychology, Tamsin Manktelow has worked as a Clinical Assistant with adolescents suffering from eating disorders, and as a Clinical Audit and Research Assistant.

She joined CDR in June 2000 as a Research Assistant and now oversees the academic arm as Scientific Development Manager. Tamsin is registered at the University of Northumbria for a part-time PhD studying the cognitive effects of eating disorders.

Andrea Zangara joined Cognitive Drug Research Ltd (CDR) in September 2000 having been a Research Assistant at University College London for a year. During this time Andrea researched the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions and has since published his work.

Currently, Andrea is a Research Associate at CDR and oversees a number of single and multi-centre projects. He is registered at the University of Northumbria for a part-time PhD examining the cognitive effects of Huperzine.

spacer
Tamsin Manktelow
spacer
spacer
spacer
Andrea Zangara
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Enables Clinical Trial Continuity through At-Home Respiratory Solutions

April 1, 2020 Ė ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced multiple options that enable trained healthcare professionals to advance respiratory clinical trials by collecting high-quality spirometry data during patient home visits. ERTís At-Home Respiratory Solutions enable clinical trial sponsors to continue developing new respiratory treatments while patient access to investigative sites is limited due to COVID19 stay-at-home mandates.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patientís particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement